Search results for "Phase IV Trial"

showing 3 items of 3 documents

Results from two pharmacotherapy trials show alcoholic smokers were more severely alcohol dependent but less prone to relapse than alcoholic non-smok…

2007

Aims: To assess the role of smoking on treatment outcome in quitting alcoholics on the background of the priming or coping hypothesis (Rohsenow et al. , [1997][1]). Methods: Data sets of placebo treated patients of the German phase III trial of naltrexone (Gastpar et al. , [2002][2]) and of acamprosate treated patients of a German phase IV trial Soyka et al. , [2002][3]) were reanalyzed. Differences between smoking and non-smoking alcoholics were evaluated using χ2-, t - or ANOVA-tests, relapse rates using survival techniques with Cox regression. Results: Smoking alcoholics differed significantly from non-smoking alcoholics regarding sociodemographic variables (e.g. more males, more often l…

AdultMalemedicine.medical_specialtyCoping (psychology)TaurineAcamprosateNarcotic AntagonistsTemperanceComorbidityPlaceboPhase IV TrialSeverity of Illness IndexNaltrexonePharmacotherapySex FactorsRecurrenceInternal medicinemedicineOdds RatioHumansPsychiatryProportional Hazards Modelsbusiness.industryProportional hazards modelSmokingGeneral MedicineMiddle AgedNaltrexoneClinical trialAlcoholismAcamprosateTreatment OutcomeMultivariate AnalysisFemalebusinessmedicine.drugAlcohol DeterrentsAlcohol and alcoholism (Oxford, Oxfordshire)
researchProduct

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutat…

2021

Pulmonary and Respiratory MedicineOncologymedicine.medical_specialtybusiness.industryAfatinibPhase IV TrialFirst line treatmentOncologyEgfr mutationInternal medicinemedicineOsimertinibIn patientbusinessmedicine.drugJournal of Thoracic Oncology
researchProduct

A nonrandomized, phase IV trial of FOLFIRI and cetuximab in first-line treatment of metastatic colorectal cancer receiving a predefined skin care and…

2014

e20724 Background: Anti-EGFR empowered chemotherapeutic regimens resulted in increased overall survival (OS) and response rates (RR). Anti-EGFR induced skin rash occurs in ~ 70% patients, and ~18% ...

OncologySkin careCancer Researchmedicine.medical_specialtyCetuximabColorectal cancerbusiness.industrymedicine.diseaseRashPhase IV TrialSurgeryFirst line treatmentOncologyInternal medicinemedicineFOLFIRIOverall survivalmedicine.symptombusinessmedicine.drugJournal of Clinical Oncology
researchProduct